利用单克隆抗体靶向清除Treg的肿瘤免疫疗法  

Treg depletion by monoclonal antibodies for cancer immunotherapy

作　　者：翟天航 张温乐 梁瑞[1] 李斌[1] ZHAI Tianhang;ZHANG Wenle;LIANG Rui;LI Bin(Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Immunology,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院,上海市免疫学研究所,上海200025

出　　处：《生命的化学》2022年第5期830-836,共7页Chemistry of Life

基　　金：国家杰出青年科学基金项目(31525008);国家自然科学基金项目(32130041,81830051,31961133011);国家重点研发计划(2019YFA0906102);上海市细胞稳态调控与疾病前沿科学研究基地项目;上海交通大学(SJTU)-香港中文大学(CUHK)联合研究合作基金项目;中央高校基本科研专项资金项目。

摘　　要：以抗PD-1/PD-L1免疫检查点为靶点,通过激活肿瘤微环境T细胞杀伤肿瘤的作用机制,已在多种实体瘤临床免疫治疗中获得验证。但以清除肿瘤微环境免疫抑制性Treg细胞为靶点,通过激活肿瘤微环境效应性免疫反应来杀伤肿瘤的作用机制目前仍有待更深入研究。本文系统探讨了以CTLA-4、TIGIT、CCR8为代表的靶向Treg表面分子的单克隆抗体疗法的最新进展及潜在作用机制,以期为更加安全有效地靶向清除Treg的抗体药物研发提供新思路,为更多晚期恶性肿瘤患者免疫治疗临床获益提供新的可选药物。The mechanism of blocking inhibitory signal in T cells to kill tumor cells,such as anti-PD-1/PDL1 monoclonal antibodies,has been approved in several different types of tumors in clinical stage.However,the mechanism of Treg depletion by monoclonal antibodies to inhibit tumor growth is controversy,especially in patients.In this paper,the advances of Treg depletion monoclonal antibodies targeting CTLA-4,TIGIT,CCR8 are summarized,and the controversies are discussed,so as to provoke new insight for further development of efficacious and safe Treg depletion therapy to benefit tumor patients.

关 键 词：肿瘤免疫治疗 TREG 抗体疗法 CTLA-4 TIGIT CCR8 

分 类 号：R730.51[医药卫生—肿瘤]